Bioage Labs, INC

BioAge Labs, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of three directors and the ratification of its auditor.

BioAge Labs reports Q1 2026 financial results, highlighting positive BGE-102 clinical data and a strong cash position to fund operations through 2029.

BioAge Labs announced positive interim Phase 1 data for BGE-102, its NLRP3 inhibitor, and completed a $132.3 million follow-on public offering, strengthening its financial position through 2029.

BioAge Labs, a clinical-stage biopharmaceutical company, announced the pricing of an upsized public offering of common stock, expecting to raise approximately $115.0 million in gross proceeds.

BioAge Labs, Inc. announced the expansion of its oral NLRP3 inhibitor BGE-102 development program into ophthalmology, targeting diabetic macular edema with a Phase 1b/2a trial planned for mid-2026.

BioAge Labs announced positive interim Phase 1 data for BGE-102, demonstrating significant reduction in inflammatory markers for cardiovascular risk.

BioAge Labs reports Q1 2026 financial results, highlighting progress on its BGE-102 clinical program and a strengthened cash position.

BioAge Labs, Inc. reported its third-quarter 2025 financial results, highlighting progress in its BGE-102 and APJ agonist programs for metabolic diseases, alongside a significant collaboration revenue increase from Novartis.

BioAge Labs, Inc. reported increased losses and R&D expenses in Q2 2025, driven by new program development and a significant Novartis collaboration, while extending its cash runway through 2029.

BioAge Labs reports its Q1 2025 financial results, highlighting the advancement of its BGE-102 NLRP3 inhibitor program for obesity and a collaboration with Novartis.

BioAge Labs reports a significant increase in cash and cash equivalents to $334.5 million following its initial public offering in the third quarter of 2024, while continuing to advance its clinical programs.

BioAge Labs, Inc. announced positive interim Phase 1 data for its lead program BGE-102, demonstrating significant hsCRP reduction, and confirmed sufficient capital to fund operations through 2029.

BioAge Labs files its 10-K, highlighting a strategic shift towards BGE-102, an NLRP3 inhibitor, for obesity treatment after discontinuing azelaprag development.

Shane Barton, an officer at BioAge Labs, Inc., reported transactions involving the acquisition and disposition of common stock and stock options, executed under a Rule 10b5-1 trading plan.

Director Vijay Satyanand Pande was granted 22,000 stock options in BioAge Labs, Inc. as part of a standard equity compensation arrangement.

Director Rekha Hemrajani was granted 22,000 stock options in BioAge Labs, Inc. as part of an equity compensation award.

Director James Healy was granted 22,000 stock options in BioAge Labs, Inc. as part of a standard equity compensation arrangement.

Director Patrick G. Enright was granted 22,000 stock options in BioAge Labs, Inc. as part of standard equity compensation.

Director Michael H. Davidson was granted 22,000 stock options in BioAge Labs, Inc. with an exercise price of $15.48.

BioAge Labs, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 10, 2026, to elect directors and ratify KPMG LLP as its independent auditor.

BioAge Labs, Inc. will hold its annual stockholders meeting virtually on June 5, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent auditor.

BioAge Labs will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent auditor.

BioAge Labs has filed a registration statement to increase its common stock offering by 575,000 shares, including an underwriter's option, representing no more than 20% of the prior offering's maximum aggregate price.

BioAge Labs is seeking to raise $180 million through an IPO to fund the development of its pipeline, including azelaprag for metabolic diseases and NLRP3 inhibitors for neuroinflammation.

BioAge Labs is seeking to raise $163.9 million through an IPO to fund the development of its therapeutics targeting metabolic diseases by leveraging insights into human aging biology.

BioAge Labs, a clinical-stage biopharmaceutical company, has filed for an initial public offering to advance its pipeline of therapeutics targeting metabolic diseases by leveraging insights into the biology of human aging.

Khosla Ventures and affiliates have filed an amendment to their Schedule 13G, reporting a decrease in beneficial ownership of BioAge Labs, Inc. to below the 5% threshold.

Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 6.51% in BioAge Labs, Inc. common stock as of March 31, 2026.

BlackRock, Inc. has reported beneficial ownership of 5.03% of BioAge Labs, Inc.'s common stock as of March 31, 2026.

Cormorant Asset Management, LP and Bihua Chen have reported a 5.69% beneficial ownership stake in BioAge Labs, Inc. common stock as of December 31, 2025.

Kristen Fortney, a key insider at BioAge Labs, Inc., has increased her beneficial ownership to 7.2% of the company's common stock as of December 31, 2025.

ADAR1 Capital Management and Daniel Schneeberger report beneficial ownership of 5.4% of BioAge Labs' common stock as of June 30, 2025.